Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARQIBO KIT vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after two or more anti-leukemia therapies
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily hepatic metabolism via CYP3A4; also undergoes biliary excretion.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 75% bound to plasma proteins, primarily to albumin and beta-globulins.
47% bound to human plasma proteins, primarily albumin.
Volume of distribution (Vd) is 4.0-7.9 L/kg (mean 5.6 L/kg), indicating extensive tissue binding and distribution into tissues, consistent with its lipophilic nature.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Not applicable; Marqibo is administered intravenously only. Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No specific dose adjustment guidelines. Use caution in patients with creatinine clearance <50 m L/min due to potential for increased exposure.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh B), reduce dose to 1.8 mg/m2 every 7 days. Mild impairment (Child-Pugh A): no adjustment necessary.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy not established in patients <18 years. Data limited to case reports; no standard dosing guidelines available.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment based on age alone. Monitor closely for increased toxicity (e.g., neurotoxicity, myelosuppression) due to potential for decreased organ function and comorbidities.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
MARQIBO is for intravenous use only. Fatal if given intrathecally. Use only with a medical provider experienced in the administration of chemotherapeutic agents. Contains vincristine sulfate, a vesicant. Ensure proper administration technique.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Extensive extravasation precautions required; neurotoxicity (peripheral neuropathy, autonomic neuropathy); hematologic toxicity (myelosuppression); gastrointestinal toxicity (constipation, ileus); hepatic impairment; monitor serum uric acid levels; embryo-fetal toxicity.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Hypersensitivity to vincristine or any component of the formulation; patients with demyelinating conditions (e.g., Charcot-Marie-Tooth syndrome); intrathecal administration.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and alter drug levels. Avoid St. John's wort as it may induce CYP3A4 and reduce efficacy. No specific food restrictions other than these. Maintain adequate hydration to prevent tumor lysis syndrome.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
No data on presence in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment and for at least 2 weeks after last dose.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No established dose adjustments for pregnancy due to lack of studies. Pharmacokinetic changes (increased volume of distribution, decreased clearance) may necessitate dose modifications based on tolerability and response. Use lowest effective dose.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
MARQIBO KIT (vincristine sulfate liposome injection) is indicated for adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory acute lymphoblastic leukemia (ALL). It is a liposomal formulation of vincristine that prolongs drug exposure and enhances tumor delivery. Administer intravenously over 1 hour at a dose of 2.25 mg/m² without a maximum dose cap, unlike standard vincristine. Do not substitute for other vincristine formulations. Monitor for neurotoxicity, including peripheral neuropathy, autonomic neuropathy (constipation, ileus), and cranial nerve palsies. Premedicate with corticosteroids and antiemetics. Avoid concomitant use of strong CYP3A4 inducers or inhibitors due to altered metabolism. Neurotoxicity is dose-limiting and may require dose reduction or discontinuation. Tumor lysis syndrome may occur; ensure adequate hydration and allopurinol. Pregnancy category D; verify pregnancy status. Extravasation management is similar to other vinca alkaloids (apply heat, hyaluronidase).
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
This medication is a form of chemotherapy given intravenously for a type of leukemia.,It may cause nerve damage; report numbness, tingling, pain, weakness, or constipation immediately.,Do not receive any live vaccines during treatment and for 6 months after.,Use effective contraception during treatment and for at least 1 month after the last dose.,Avoid grapefruit juice and St. John's wort while on this medication.,Drink plenty of fluids to prevent tumor lysis syndrome.,Report any signs of infection (fever, chills) or bleeding (easy bruising, black stools).
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARQIBO KIT vs CLOLAR, answered by our medical review team.
MARQIBO KIT is a Antineoplastic Agent that works by Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARQIBO KIT and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARQIBO KIT is: 2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARQIBO KIT and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARQIBO KIT is classified as Category C. Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.